TG Therapeutics (TGTX) to Release Quarterly Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of $0.27 per share and revenue of $147.76 million for the quarter.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.16). The business had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The business’s revenue for the quarter was up 90.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.07) EPS. On average, analysts expect TG Therapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

TG Therapeutics Price Performance

TGTX opened at $35.02 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.02 and a quick ratio of 3.04. The company has a market capitalization of $5.56 billion, a price-to-earnings ratio of 145.92 and a beta of 1.95. The firm’s fifty day moving average price is $36.83 and its two-hundred day moving average price is $36.01. TG Therapeutics has a 1 year low of $16.65 and a 1 year high of $46.48.

Analyst Ratings Changes

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 price objective on the stock in a report on Thursday, July 10th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.80.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the transaction, the director directly owned 228,816 shares of the company’s stock, valued at $8,452,463.04. The trade was a 4.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.64% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. NewEdge Advisors LLC boosted its holdings in shares of TG Therapeutics by 9.6% in the 1st quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock worth $299,000 after buying an additional 665 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of TG Therapeutics by 16.4% in the 1st quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock worth $2,985,000 after buying an additional 10,660 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of TG Therapeutics by 5.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock worth $11,319,000 after buying an additional 14,689 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of TG Therapeutics by 21.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock worth $75,683,000 after buying an additional 345,059 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.